Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nexstim on its dual listing on First North Finland and First North Sweden
Mandate

Vinge advises Nexstim on its dual listing on First North Finland and First North Sweden

November 14, 2014

Vinge advised Nexstim on its IPO and dual listing of shares on First North Finland and First North Sweden. In the IPO, Nexstim issued 2,408,339 news shares at a subscription price of EUR 6.35 per share, amounting to gross proceeds of roughly EUR 15.3 million. Trading in the company's shares on First North Finland and First North Sweden commenced on 14 November 2014. The transaction is the first ever dual listing on the First North exchanges maintained by Nasdaq.

Nexstim is a medical technology company based in Finland that aims to improve rehabilitation for stroke patients. 

Vinge’s team primarily consisted of Jesper Schönbeck, Joakim Hagberg, Tora Hansjons and Nils Fredrik Dehlin.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

 HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

 Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

 Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026